Detail akcie Rallybio Rg online

Business Summary: Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Rallybio Corp revenues decreased 50% to $212K. Net income totaled $35.4M vs. loss of $19.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net Income reflects clinical-stage biotechnology segment loss decrease of 27% to $14.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$3.41758 to $6.20652.